《異動股》瑞誠中國傳媒(01640.HK)飆升1.4倍創價量齊創逾一年高
鳳凰衛視(02008.HK)易主紫荊香港及信德集團(00242.HK),該股今天曾急漲36%至1.06元;瑞誠中國傳媒(01640.HK)借勢升破52周高位0.415元,最高見0.81元,為去年3月初以來最高,現造0.78元,飆升1.4倍,一向稀疏成交激增至5,130萬股,為近年半月罕見,涉資3,250萬元。
瑞誠是內地電視廣告營銷商,去年純利按年跌92%至284.4萬人民幣。該股於2019年11月以每股1.25元來港上市,股價於2019年12月曾升至3.55元無以為繼後,反覆回落。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.